Investigational drug · Phase 2
SSGJ-705
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Locally Advanced, Recurrent or Metastatic Malignancies, Locally Advanced (Unresectable) or Metastatic Solid Tumors.
Phase 2Last checked: Nov 20, 2026Latest source record: Jul 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "SSGJ-705"
First trial start
2025
Jul 30, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SSGJ-705", any sponsor or status.
Conditions studied
As listed on its trial records.
- Locally Advanced, Recurrent or Metastatic Malignancies
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "SSGJ-705" as an intervention, largest first.
Shenyang Sunshine Pharmaceutical Co., LTD.Industry
NCT07022002 · 340 participants (planned) · Start Jul 30, 2025 · Primary completion Dec 31, 2026
Drug: SSGJ-705; PD-1/L1 inhibitor combined with chemotherapy and 1 more · For: Locally Advanced, Recurrent or Metastatic Malignancies
Sites: Hangzhou, China
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Industry
NCT06390774 · 180 participants (planned) · Start May 30, 2024 · Primary completion Dec 2026
Drug: SSGJ-705 · For: Locally Advanced, Recurrent or Metastatic Malignancies
Sites: Jinan, China
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Industry
NCT05145179 · 162 participants (planned) · Start Dec 1, 2021 · Primary completion Dec 1, 2023
Drug: SSGJ-705 · For: Receptor, ErbB-2
- SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid TumorsPivotal-lookingRecruiting
Shenyang Sunshine Pharmaceutical Co., LTD.Industry
NCT07646626 · 150 participants (planned) · Start Jul 17, 2026 · Primary completion Jun 30, 2027
Drug: SSGJ-705; SSGJ-612 and 1 more · For: Locally Advanced (Unresectable) or Metastatic Solid Tumors
Sites: Hangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.